Subtopic Deep Dive
Budesonide Therapy in Microscopic Colitis
Research Guide
What is Budesonide Therapy in Microscopic Colitis?
Budesonide therapy in microscopic colitis refers to the use of this topically acting glucocorticoid as first-line treatment for collagenous and lymphocytic colitis, demonstrating efficacy in inducing clinical remission through randomized controlled trials.
Key trials include Baert et al. (2002, 274 citations) showing budesonide's superiority over placebo in collagenous colitis with histologic follow-up, and Bonderup et al. (2003, 229 citations) confirming clinical and morphometric improvements. These studies establish 9 mg daily dosing for 6-8 weeks as standard. Over 500 citations across foundational works support its role in guidelines (Magro et al., 2013, 692 citations).
Why It Matters
Budesonide reduces systemic corticosteroid side effects due to high first-pass metabolism, enabling safe management of chronic diarrhea in microscopic colitis patients (Baert et al., 2002). Optimized regimens from RCTs inform ECCO guidelines, lowering relapse rates and hospitalization (Bonderup et al., 2003; Bohr et al., 1996). In clinical practice, it guides therapy for 10-20% of chronic diarrhea cases, improving quality of life without colectomy risks (Olesen et al., 2004).
Key Research Challenges
Relapse After Remission
High relapse rates post-budesonide induction necessitate maintenance strategies, with limited long-term data (Baert et al., 2002). Trials show 60-80% recurrence within 6 months without ongoing therapy (Bonderup et al., 2003). Optimal taper schedules remain undefined.
Collagenous vs Lymphocytic Differentiation
Efficacy may differ between subtypes, requiring subtype-specific dosing (Bohr et al., 1996). Histopathology consensus aids diagnosis but trials underpower subgroup analysis (Magro et al., 2013). Head-to-head comparisons are scarce.
Long-Term Safety Profiling
Adrenal suppression and bone density risks need monitoring in extended use (Olesen et al., 2004). No large cohorts track outcomes beyond 1 year. Comparative safety versus mesalazine lacks RCTs.
Essential Papers
European consensus on the histopathology of inflammatory bowel disease
Fernando Magro, Cord Langner, Ann Driessen et al. · 2013 · Journal of Crohn s and Colitis · 692 citations
The histologic examination of endoscopic biopsies or resection specimens remains a key step in the work-up of affected inflammatory bowel disease (IBD) patients and can be used for diagnosis and di...
European evidence based consensus on the diagnosis and management of Crohn’s disease: current management
Simon Travis, E F Stange, M Lémann et al. · 2006 · Gut · 603 citations
This second section of the European Crohn’s and Colitis Organisation (ECCO) Consensus on the management of Crohn’s disease concerns treatment of active disease, maintenance of medically induced rem...
Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients.
Johan Bohr, Curt Tysk, S. Eriksson et al. · 1996 · Gut · 560 citations
BACKGROUND: Data on collagenous colitis have been based on a limited number of patients. AIMS: To obtain more information on this disease from a register set up at Orebro Medical Center Hospital. P...
Severe Spruelike Enteropathy Associated With Olmesartan
Alberto Rubio‐Tapia, Margot L. Herman, Jonas F. Ludvigsson et al. · 2012 · Mayo Clinic Proceedings · 483 citations
Advances in Diagnosis and Management of Celiac Disease
Ciarán P. Kelly, Julio C. Bai, Edwin Liu et al. · 2015 · Gastroenterology · 315 citations
Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition
Ramesh Arasaradnam, Steven R. Brown, Alastair Forbes et al. · 2018 · Gut · 302 citations
Chronic diarrhoea is a common problem, hence clear guidance on investigations is required. This is an updated guideline from 2003 for the investigations of chronic diarrhoea commissioned by the Cli...
Budesonide in collagenous colitis: A double-blind placebo-controlled trial with histologic follow-up
Filip Baert, Alain Schmit, Geert D’Haens et al. · 2002 · Gastroenterology · 274 citations
Reading Guide
Foundational Papers
Start with Baert et al. (2002, 274 citations) for pivotal RCT evidence, then Bonderup et al. (2003, 229 citations) for morphometric validation, and Bohr et al. (1996, 560 citations) for patient characteristics.
Recent Advances
Magro et al. (2013, 692 citations) for histopathology consensus; Arasaradnam et al. (2018, 302 citations) for diarrhea guidelines incorporating budesonide.
Core Methods
Double-blind RCTs with stool frequency endpoints, histologic scoring (Magro et al., 2013), and subepithelial collagen band morphometry (Bonderup et al., 2003).
How PapersFlow Helps You Research Budesonide Therapy in Microscopic Colitis
Discover & Search
Research Agent uses searchPapers('Budesonide collagenous colitis RCT') to retrieve Baert et al. (2002), then citationGraph to map 274 citing papers on relapse prevention, and findSimilarPapers to uncover Bonderup et al. (2003) for morphometric endpoints.
Analyze & Verify
Analysis Agent applies readPaperContent on Baert et al. (2002) to extract remission rates, verifyResponse with CoVe against Olesen et al. (2004) for lymphocytic colitis consistency, and runPythonAnalysis to meta-analyze odds ratios via pandas from trial tables, graded by GRADE for moderate evidence quality.
Synthesize & Write
Synthesis Agent detects gaps in maintenance dosing via contradiction flagging across Bohr et al. (1996) and Bonderup et al. (2003), while Writing Agent uses latexEditText for guideline drafts, latexSyncCitations to integrate 10 papers, and latexCompile for publication-ready PDFs with exportMermaid timelines of therapy phases.
Use Cases
"Extract relapse rates from budesonide trials in collagenous colitis and plot survival curve."
Research Agent → searchPapers → Analysis Agent → readPaperContent (Baert 2002, Bonderup 2003) → runPythonAnalysis (pandas survival analysis with matplotlib Kaplan-Meier) → researcher gets CSV/PNG of relapse curves.
"Draft LaTeX review section on budesonide dosing for microscopic colitis guidelines."
Synthesis Agent → gap detection → Writing Agent → latexEditText (induction/maintenance regimens) → latexSyncCitations (Baert 2002 et al.) → latexCompile → researcher gets compiled PDF with cited trial summaries.
"Find code for analyzing histologic collagen band thickness in colitis trials."
Research Agent → paperExtractUrls (Magro 2013) → paperFindGithubRepo → githubRepoInspect (image analysis scripts) → researcher gets Python repo for morphometric validation from Bonderup 2003 data.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ budesonide papers) → citationGraph → GRADE grading → structured report on efficacy vs placebo. DeepScan applies 7-step analysis with CoVe checkpoints on Baert (2002) for remission verification. Theorizer generates hypotheses on low-dose maintenance from relapse patterns in Bohr (1996) and Olesen (2004).
Frequently Asked Questions
What is budesonide therapy in microscopic colitis?
Budesonide is a poorly absorbed glucocorticoid used at 9 mg/day for 6-8 weeks to induce remission in collagenous and lymphocytic colitis (Baert et al., 2002).
What methods prove budesonide efficacy?
Double-blind placebo-controlled RCTs with histologic and morphometric endpoints confirm superiority (Baert et al., 2002; Bonderup et al., 2003).
What are key papers?
Baert et al. (2002, 274 citations) for collagenous colitis trial; Bonderup et al. (2003, 229 citations) for morphometric analysis; Bohr et al. (1996, 560 citations) for clinical presentation.
What open problems exist?
Optimal maintenance dosing, subtype differences, and long-term safety data beyond 1 year remain unresolved (Olesen et al., 2004).
Research Microscopic Colitis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Budesonide Therapy in Microscopic Colitis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Microscopic Colitis Research Guide